Ellevest Inc’s Avidity Biosciences RNAM Stock Holding History

Ellevest Inc’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15	Closed	-$230	–	1352
2023 Q1	$230	Buy	+15	New	+$330	﹤0.01%	1754

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ellevest Inc's RNAM Position: Q2 2023 in Review

Ellevest Inc sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 15 shares — an estimated $230 sold.

Ellevest Inc first reported a position in RNAM in Q1 2023 and held it in 1 quarter. The position peaked at $230 in Q1 2023. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

Ellevest Inc reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 15 Avidity Biosciences shares in Q2 2023, an estimated $230.
Ellevest Inc first reported a position in Avidity Biosciences in Q1 2023 and held it in 1 quarter.
Ellevest Inc's Avidity Biosciences position peaked at $230 in Q1 2023.
143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.